(Q43011186)

12 November 2017

title

A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis (English)

1 reference

amyotrophic lateral sclerosis

12 November 2017

0 references

0 references

placebo

1 reference

based on heuristic

inferred from title

placebo-controlled trial

1 reference

Anabela Pinto

6

0 references

Susana Pinto

object named as

Susana Pinto

2

0 references

Mamede de Carvalho

object named as

Mamede de Carvalho

1

0 references

Teresinha Evangelista

4

object named as

Teresinha Evangelista

1 reference

12 November 2017

João Costa

3

1 reference

12 November 2017

Bemjamim Ohana

5

1 reference

12 November 2017

publication date

1 October 2010

1 reference

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

12 November 2017

published in

1 reference

12 November 2017

volume

11

1 reference

12 November 2017

issue

5

1 reference

12 November 2017

page(s)

456-460

1 reference

Excitotoxicity and amyotrophic lateral sclerosis.

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2010.498521

Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2010.498521

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2010.498521

Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2010.498521

Oral administration of memantine prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2010.498521

Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2010.498521

Acute hepatitis after riluzole administration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2010.498521

Neurophysiological measures in amyotrophic lateral sclerosis: markers of progression in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2010.498521

The pharmacology and mechanism of action of riluzole

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2010.498521

Clinical trials in ALS: a review of the role of clinical and neurophysiological measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2010.498521

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2010.498521

Can Selection of Rapidly Progressing Patients Shorten Clinical Trials in Amyotrophic Lateral Sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2010.498521

Quantitating progression in ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F17482968.2010.498521

10.3109/17482968.2010.498521

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference